About Rhythm Biosciences
Unlike traditional screening methods that are invasive, uncomfortable, and often avoided, we’re developing precise and accessible screening solutions, that empower patients and healthcare systems with critical insights.
Rhythm is not just a medical technology company, we’re health innovators driven by a singular purpose. Our work is about knowledge, reducing unnecessary medical procedures, alleviating the strain on healthcare systems, and most importantly, giving people the earliest possible chance to take control of their health.
Rhythm is building a future where cancer is identified early and treated effectively.
Vision
To be a pioneering force in early cancer detection through innovative, accessible, and accurate diagnostic technologies that:
- Improve patient outcomes and potentially save lives
- Identify risk for the personalised management of health
- Simplify cancer screening processes
- Reduce healthcare costs
We are transforming cancer detection and management through:
- Risk assessment – Identifying an individual’s likelihood of developing specific cancers through advanced genetic and clinical analysis
- Early detection – Finding cancer at its earliest, most treatable stages using innovative non-invasive diagnostics
- Characterisation – Understanding the specific nature and behaviour of detected cancers through detailed molecular analysis to determine cancer type, severity, and optimal treatment approaches.
- Treatment support – Providing ongoing diagnostic insights that help clinicians monitor treatment effectiveness and make informed decisions about patient care plans
Pipeline
Our combined platforms support a highly comprehensive approach to cancer diagnostics which addresses a huge total available market.
Our Mission
Rhythm Biosciences Timeline
CSIRO Research and Development
Rhythm Bio Lists on the ASX
Development Program Commences
Clinical Trial Program Commences
ISO Certification
Patents Secured in 21 Countries
Global Manufacturer Appointed
Clinical Trial Complete (RHY-001)
CE Mark Granted for ColoSTAT®
ColoSTAT® Authorised for Sale in
UKCA Mark Granted and Strategic Partnership with LINK Medical Solutions
RHY001 Study - Submit Publication
Alpha Version of the Multiplex Antibody Detection Kits Received
Multiplex Kit Validation
Market Entry
Pipeline Activities - Other Cancers
Pipeline
Leveraging the proprietary immunoassay, developed for our ColoSTAT® blood test, Rhythm Biosciences is investigating the feasibility of using this technology to establish diagnostic tests for detection of other cancer types.
Cancer Target
Collaborator
Theoretical Analysis of Biomarker Potential
Serum and Algorithm Analysis
Risk Analysis ➝ Enter Stage 2
Breast
Agilex Biolabs P/L
Lung
Baker Institute
Gastric
Nexomics
Cervix
On Hold
Pancreas
On Hold
About us:
Contact
Rhythm Biosciences
Bio21 Institute
30 Flemington Road
Parkville VIC 3010
Australia
